Cyclosporine A Pretreatment and Kidney Graft Function

Organ donors included in the study are randomized to a control group receiving a placebo or an intervention group receiving 2.5 mg/kg of cyclosporine A before organ procurement. In the operating theater organs are harvested. Thereafter, harvested kidneys from these patients are transplanted to chronic kidney insufficiency patients. The management of transplanted patients is performed as usual. According to the pretreatment of the transplant, delayed graft function during the first week (need of at least one dialysis session) was evaluated as well as kidney function at different timepoints (slow graft function, estimated creatinine clearance on day 3 and 7, acute and chronic graft rejection), length of hospital stay and mortality during the first year after transplantation.

Inclusion criteria

For organ donors:

• Male and females aged 18 to 80 years
• Brain death

Inclusion criteria

for organ recipients:

• Male and females aged 18 to 80 years
• Indication of kidney transplantation
• Informed consent

Exclusion criteria

For organ donors:

• Contra-indication for multiorgan procurement (infections, cancer, etc)
• Preexistent chronic renal failure.
• Refusal for organ procurement by the donor (confirmed by the French national register or reported by the next-of-kin).

Exclusion criteria

for organ recipients:

• Need for a double kidney transplantation.
• Need for a multiorgan transplantation